OBJECTIVES: To evaluate the effectiveness of pramipexole treatment in patients with primary Restless Legs Syndrome (RLS) and, secondarily, the effect on work productivity impairment associated with RLS. METHODS: This was an open-label, 12
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EFFECTIVENESS OF PRAMIPEXOLE IN THE TREATMENT OF RLS AND THE EFFECT ON WORK PRODUCTIVITY: A 12-WEEKS NON-INTERVENTIONAL TRIAL IN PATIENTS WITH PRIMARY RESTLESS LEGS SYNDROM (RLS)
Eisensehr I 1 , Möller C 2 , Köster J 2 , Brüggenjürgen B 3 1 Neurologie in der Sendlinger Straße, München, Germany, 2 Boehringer-Ingelheim Pharma GmbH & Co KG, Ingelheim am Rhein, Germany, 3 Charité University Medical Center, Berlin, Germany OBJECTIVES: To evaluate the effectiveness of pramipexole treatment in patients with primary Restless Legs Syndrome (RLS) and, secondarily, the effect on work productivity impairment associated with RLS. METHODS: This was an open-label, 12 week-prospective, non-controlled, non-interventional trial in patients with primary moderate to severe RLS being treated with the non-ergot dopamine agonist pramipexole by general practitioners and internists across Germany under routine conditions. Work productivity impairment was assessed by the Work Productivity and Activity Impairment Questionnaire (WPAI), RLS severity was measured by the International RLS Study Group Rating Scale (IRLS). RESULTS: A total of 2,546 patients suffering from moderate to severe RLS were evaluated at 904 sites. The mean age of the patients was 64.8 years and 67.8% were female. Median treatment duration was 92 days. Patients were starting with a median initial pramipexole dose of 0.088 mg/d, were flexibly titrated and had a final maintenance dose of 0.35 mg/d. RLS severity was significantly improved: IRLS mean score was 25.7 at baseline and 9.6 at the final visit. From the total population 539 patients (21.2%) were in paid labour. The mean age of this sub-population was 52.1 years; 58.1% were female. Impairment while working due to RLS was reduced by 30% (median) in a subgroup of 436 patients, who reported impairment at baseline. In 162 patients reporting 'Missing from work due to health problems' at baseline, a 6.1 hours/week (mean) reduction at the final visit was assessed by the WPAI, which translates into an average reduction in productivity loss for working RLS patients of €1642 in Germany. CONCLUSION: Pramipexole showed to be highly effective in the treatment of RLS in routine care, as substantiated by IRLS. Work productivity was substantially increased and impairment while working due to RLS-symptoms was reduced in patients being in paid labour.
OSTEOPOROSIS-Clinical Outcomes Studies

POS1 EFFICACY OF ZOLEDRONIC ACID RELATIVE TO OTHER TREATMENTS FOR VERTEBRAL FRACTURES IN OSTEOPOROSIS: RESULTS OF A BAYESIAN MIXED TREATMENT COMPARISON
Bergman G 1 , Olson M 2 , Huels J 2 , Jansen JP 1 1 Mapi Values, Houten, The Netherlands, 2 Novartis Pharma AG, Basel, Switzerland OBJECTIVES: To evaluate the efficacy of zoledronic acid relative to other anti-resorptive interventions regarding the prevention of vertebral fractures in postmenopausal women with osteoporosis. METHODS: Twelve randomized placebo controlled trials investigating the effects of zoledronic acid (1 study), alendronate (3), risedronate (2), ibandronate (1), etidronate (1), calcitonin (1), ralixofene (1), or strontium ranelate (2) in terms of fractures with a follow-up of 3 years (or 2 years if used for registration purposes) were identified with a systematic literature search. The endpoint of interest was morphometric vertebral fractures. Results of all trials were analyzed simultaneously with a Bayesian mixed treatment comparison (MTC). MTC is an extension of traditional meta-analysis by including multiple different pairwise comparisons across the range of different interventions. With MTC the relative treatment effect of one intervention to another can be obtained in the absence of head-to-head evidence. In contrast to a frequentist approach, a Bayesian analysis allows for direct probabilistic inferences. Outcomes were analyzed using a random effects model. RESULTS: There is a 73.6% probability that zoledronic acid shows the greatest reduction in vertebral fractures of all interventions compared, followed by etidronate (23.2% probability) and ibandronate (1.8%). Zoledronic acid showed an OR of 0.28 (95% Credible Interval 0.19-0.40) relative to placebo, an OR of 0.62 relative to etidronate, and an OR of 0.55 relative to ibandronate. Corresponding probabilities that zoledronic provides a greater vertebral risk reduction are 99.9%, 79.6%, and 98.9% compared to placebo, etidronate, and ibandronate, respectively. Similar comparisons are under investigation for other fracture endpoints. CONCLUSION: Of the available treatments for osteoporosis, zoledronic acid is one of the treatments that provide greatest fracture risk reductions in general. Furthermore zoledronic acid showed greatest reductions regarding vertebral fractures.
POS2 CORRELATION BETWEEN PREDICTORS AND SUBSEQUENT SURGICAL MANAGEMENT FOLLOWING INTERNAL FIXATION OF FEMORAL NECK FRACTURES
Sebestyén A 1 , Tóth F 2 , Sándor J 2 , Gulácsi L 3 , Brodszky V 3 , Nyárády J 2 , Boncz I 2 1 National Health Insurance Fund Administration, Pécs, Hungary, 2 University of Pécs, Pécs, Hungary, 3 Corvinus University of Budapest, Budapest, Hungary OBJECTIVES: Regarding intracapsular femoral neck fractures, the main focus of research is the correlation between fracturerelated complications and prognostic factors. The purpose of this study was to evaluate the correlation between complications required surgery (fracture-related treatment) and, among others, several less extensively investigated prognostic factors (day of surgery, co-morbidities, hospital type) in a 2-year period following internal fixation in young adults with intracapsular femoral neck fracture. METHODS: Retrospective analysis of femoral neck fractures occurred in Hungary in 2000, based on data obtained from the National Health Fund Administration. The data were validated and completed by a questionnaire carried out Abstracts A393 in all 60 institutions enrolled. Patients with polytrauma were not included into the study. The effects of prognostic factors were analysed by uni-and multivariate logistic regression (p″T0.05) in three groups: 1) all fracture-related treatments; 2) nonprosthetic; and 3) prosthetic treatments. RESULTS: Out of 413 patients, 17.92% required further fracture-related treatment. In 7.75% non-prosthetic, and in 10.17% prosthetic treatment was performed. We demonstrated the odds ratios by multivariate regression analysis according to risk factors [95% confidence interval, CI] are also given. .568] were associated with significantly increased risk for further surgery. CONCLUSION: To reduce the influence of risk factors, standardization of the substantive traumatologic and orthopedic professional guidelines, as well as the introduction of common orthopedic-trauma patient care (British model) are suggested. To achieve high-quality standardized patient management, personal and material conditions are required to be accessible every day of the week. In the presence of co-morbidities, reduction of their harmful effects should be a major consideration by focusing on the patient both in the peri-and postoperative periods.
POS3 THE ROLE OF SURGICAL DELAY ON EARLY MORTALITY IN PATIENTS WITH FEMORAL NECK FRACTURE
Sebestyén A 1 , Sándor J 2 , Nyárády J 2 , Betlehem J 2 , Gulácsi L 3 , Péntek M 4 , Boncz I 2 1 National Health Insurance Fund Administration, Pécs, Hungary, 2 University of Pécs, Pécs, Hungary, 3 Corvinus University of Budapest, Budapest, Hungary, 4 Flor Ferenc County Hospital, Kistarcsa, Hungary OBJECTIVES: The aim of the present study was to investigate the relationship between the delay of definitive surgical treatment and mortality rates occurring within 30 days post-injury in patients aged 60 or older with femoral neck fracture. METHODS: Data were obtained from the database of the National Health Insurance Fund and from the questionnaire survey carried out by the institutions providing the treatment. Logistic regression analysis was performed to analyse the correlation between mortality risks within 30 days and delayed surgery in patients operated at 12-24 h, 24-48 h or after 48 h post-injury in comparison with mortality risks associated with early (within 12 h) treatment. RESULTS: The number of patients meeting the case definition criteria was 3777 with the average age of 77.97 years. Mortality rates in four groups were 7.7%, 10.5%, 10.5% and 9.4%, respectively. According to multiple regression analysis, all three groups (12-24 h, 24-48 h and the over 48 h) showed a trend to increased mortality risks but this was not statistically significant (OR12-24 h = 1.301 CI12-24 h: 0.945-1.791, p = 0.106; OR24-48 h = 1.384 CI24-48 h: 0.932-2.056, p = 0.108; OR48 h <= .246 CI48 h <: 0.950-1.635, p = 0.113). Sex, age and accompanying diseases significantly influenced early mortality, while early postoperative complications did not have a significant impact on the mortality risks. CONCLUSION: The results of the present study indicate the importance of early surgery in the treatment of femoral neck fractures in order to decrease early mortality associated with the disease in the elderly populations. Our results highlight the importance of further evaluating the reasons behind the delay in the surgical treatment (problems during treatment, difficulties in surgical access, co-morbidity etc.), especially in cases when surgery is performed with a 24 h or longer post-injury delay in order to determine factors that influence the prognostic significance of surgical delay in the case of different patient groups.
OSTEOPOROSIS-Cost Studies
POS4 ECONOMIC IMPACT OF FRENCH NEW GUIDELINES ON POST-MENOPAUSAL OSTEOPOROSIS DIAGNOSIS
Cotte FE 1 , Fardellone P 2 , Roux C 3 , Lespessailles E 4 , Gaudin AF 1 1 GlaxoSmithKline France, Marly le Roi, France, 2 CHU Nord Hospital, Amiens, France, 3 Cochin Hospital, Paris, France, 4 CHR Orleans, Orleans, France OBJECTIVES: With at least 150,000 osteoporotic fractures in France, annual cost for osteoporosis consequences was estimated to about €600 millions. Poor diagnosis rate led French authorities to decide reimbursement of bone mineral densitometry (BMD) for osteoporosis high risk population in July 2006 (i.e. postmenopausal women with at least one risk factor as defined by the National Union of the Health Insurance Services). Our study was aimed to estimate the prevalence of osteoporosis risk factors so as to assess the economic impact of this case-finding strategy. METHODS: This cross-sectional epidemiological survey was carried out within a representative population of women aged 45 years and over constituted using a stratified random sampling method (age, sex, socio-professional group, and employment status). Face-to-face home interviews determined eligibility of women for BMD-screening and whether they had underwent a BMD and received a diagnosis of osteoporosis. Direct costs were assessed from the perspective of the health care providers (i.e. BMD and physician consultation: 39.96€ and 18.60€ respectively). RESULTS: In our sample, 79.6% (2081) of women were menopaused. 51.8% of them were eligible for BMD-screening and 11.6%were already diagnosed by BMD with osteoporosis. Among the diagnosed women, a third (31.0%) didn't have any risk factors and would not be eligible for the screening. Based on these results, number of French eligible women for BMD-screening would be about 5.8 millions associated with a total cost of €342 millions. Women diagnosed by BMD were 1.3 million and could also achieve 2.3 millions representing a cost per patient screened of 165€. CONCLUSION: According to this study, the French case-finding strategy for postmenopausal osteoporosis would cost €342 millions and would lead to treat an additional one million patients.
POS5 LITERATURE REVIEW ON THE COSTS OF NON-COMPLIANCE IN OSTEOPOROSIS
Cowell W 1 , Palmer K 1 , Hughes D 2 1 Roche, Welwyn Garden City, UK, 2 University of Wales, Bangor, Bangor, UK OBJECTIVES: Medication compliance is a significant factor contributing to the clinical-and cost-effectiveness of therapy. This study aimed to investigate the evidence on the overall cost of non-compliance with medication, taking osteoporosis therapy as an example. METHODS: The specific question addressed was "What are the direct medical health care costs of non-compliance and non-persistence in osteoporosis". A Literature review was conducted to search for publications presenting work under the broad terms "costs", "compliance/persistence" and "osteoporosis". The databases searched were Medline, EMBASE, and the Cochrane Library. The listings were then appraised to identify those papers relevant to the study question and for inclusion in
